EMA Recommends Caution For Pfizer's Xeljanz

The Agency Has Also Issued Restrictions For Sanofi's Lemtrada

 
• By Neena Brizmohun
  
Healthy human red bloodcells abstract concept background - Image
The EMA warns that Xeljanz can cause blood clots in high-risk patients • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

More from Geography